Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Electrum Advances AMT Geophysical Survey Identifying Additional Drill Targets (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
Nurexone Biologic Inc
V.NRX
Alternate Symbol(s):
NRXBF
Healthcare
Biotechnology
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It develops and commercializes the ExoTherapy platform for production of exosome-loaded nanodrugs. The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of...
paralysis caused by spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat traumatic brain injuries and other neurological conditions. Its technology includes ExoPTEN for the treatment of acute spinal cord injury and glaucoma; and Exosomes as a drug delivery system for regeneration and healing of specific tissues. The company was founded in 2020 and is based in Toronto, Canada.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (TSXV:NRX)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
Next
(8)
•••
Investorsnews
X
Post by
Investorsnews
on Jul 21, 2025 7:17pm
Read the FRC analyst note on NurExone’s preclinical success
Disseminated on behalf of NurExone Biologic Inc. (TSXV: NRX / OTCQB: NRXBF / FSE: J90). Update: NurExone’s ExoPTEN showed strong preclinical results, improving motor function in spinal cord injury
...more
(83)
•••
cmarketinsights
X
Post by
cmarketinsights
on Mar 18, 2025 2:41pm
FRC analysts' Opinion on this develop
NurExone Biologic provided updates on research related to spinal cord injury treatment. Analysts have commented on the latest study outcomes: Read more Disclaimer: This article and research
...more
Clean air specialist mitigating mercury emissions from US coal-fired power plants
posted Jan 22, 2026 9:00am by
Birchtech Corp.
-
|
The small-cap company, positioned for long-term growth with a profitable business and an ongoing expansion into water purification is eyeing an NYSE American listing ...read more
(0)
•••
PressRelease
X
Post by
PressRelease
on Feb 05, 2025 4:04pm
New Press Release - NurExone Forms Exo-Top Inc. in the U.S. for Exosome Manufacture and Commercialization
TORONTO and HAIFA, Israel, Feb. 05, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (“NurExone” or the “Company”) is pleased to announce the formation of a U.S.-based subsidiary, Exo-Top Inc. (“Exo-Top”), that is expected to advance good manufacturing...
read article.
(61)
•••
Flintstone60
X
Post by
Flintstone60
on Jan 31, 2025 5:08am
Linkedin Post
CEO Lior Shaltiel, PhD on Linkedin: A huge hats off to NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90) Scientific Advisory Board (SAB) member, Prof. Michael Belkin, who will be receiving the
...more
(83)
•••
cmarketinsights
X
Post by
cmarketinsights
on Jan 27, 2025 3:52pm
FRC analysts' Opinion on this develop
R&D Boost: Funding secured to accelerate development of ExoPTEN, a groundbreaking treatment for spinal cord injuries. What’s next for this biotech innovator? Read the comment
(0)
•••
PressRelease
X
Post by
PressRelease
on Jan 21, 2025 4:21pm
New Press Release - NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director
TORONTO and HAIFA, Israel, Jan. 21, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (“NurExone” or the “Company”), a developer of exosome-based therapies for regenerative medicine, is pleased to announce that, subject to TSX Venture Exchange (“TSXV...
read article.
(37)
•••
javaman12
X
Post by
javaman12
on Jan 14, 2025 11:02pm
Exosome Based Therapies
NurExone chose to base its ultimate drug delivery platform on exosomes-nanosized extracellular vesicles-due to their natural ability to reach inflamed or damaged tissue. By loading exosomes with
...more
(37)
•••
javaman12
X
Post by
javaman12
on Jan 14, 2025 10:25pm
2025 Is The Critical Year For FDA Approval!
A near term 'Investigational New Drug' (IND) submission will be quickly followed by Phase I/IIa Human trials to help wheel chair bound victims get up and walking once again! After the IND
...more
(83)
•••
cmarketinsights
X
Post by
cmarketinsights
on Jan 14, 2025 5:56pm
🧬 Exosome Therapy Milestone 🧬
NurExone has secured a master cell bank for its innovative exosome-based therapy, ExoPTEN, targeting acute spinal cord injury (SCI). With Orphan Drug Designation from the FDA and EMA, phase one trials
...more
(37)
•••
javaman12
X
Post by
javaman12
on Jan 11, 2025 10:36pm
Is This Biotech Now Poised For It's First Clinical Trials?
Imagine if it were possible to cure most neurological damage (like an accidental spinal paralysis, stroke or damage to the eye) with a simple squirt in the nose by the use of a simple nasal inhaler
...more
(83)
•••
cmarketinsights
X
Post by
cmarketinsights
on Jan 03, 2025 5:34pm
A New Frontier in Regenerative Medicine
A New Frontier in Regenerative Medicine NurExone Biologic Inc. (TSXV: NRX) , an Israeli biotech company, is developing a novel exosome-based drug delivery platform aimed at treating central nervous
...more
(54)
•••
Jolly09
X
Post by
Jolly09
on Dec 17, 2024 3:54pm
Analyst coverage report
Fundamental Research report: A Potential Breakthrough in Spinal Cord and Optic Nerve Injury Treatment https://nurexone.com/wp-content/uploads/2024/12/Nurexone-Dec-2024-Initiating.pdf
(54)
•••
Jolly09
X
Post by
Jolly09
on Dec 10, 2024 11:13am
New research report target share price of $3.05
NRXBF Announces Important Test Results https://scr.zacks.com/news/news-details/2024/NRXBF-Announces-Important-Test-Results/default.aspx
(61)
•••
Flintstone60
X
Post by
Flintstone60
on Dec 05, 2024 4:55am
News ahead?
We're evaluating the final data from our pre-clinical study on ExoPTEN's effects in a glaucoma model, in collaboration with the Goldschleger Eye Institute at Sheba Medical Center, Tel Hashomer
...more
(12)
•••
GoldCanuck28
X
Post by
GoldCanuck28
on Nov 14, 2024 12:00pm
More exciting news!
https://stockhouse.com/news/press-releases/2024/11/13/nurexone-biologic-secures-ema-orphan-status-for-exopten-in-spinal-cord-injury
Prev
1
2
3
4
5
6
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Vertical integration could reshape this scaling beverage brand’s long-term outlook
A transformational year in 2025 and positive outlook for growth in revenue and profitability in 2026
A clean tech company on the verge of transformational growth plans to uplist to major US exchange
Podcasts